23Mar 2023
Personalized Systemic Therapy Offers New Options for HER2-Negative Breast Cancer Patients

Personalized Systemic Therapy Offers New Options for HER2-Negative Breast Cancer Patients

The article discusses hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer, which is the most common type of breast cancer. Endocrine therapy is the main treatment for both early and late-stage disease, and combinations with cyclin-dependent kinase 4/6 inhibitors have improved outcomes. Chemotherapy is used based on stage and tumor biology, and new therapies such as novel endocrine agents and antibody-drug conjugates are changing the treatment landscape. The article emphasizes the importance of defining the optimal sequence of treatment to maximize clinical benefit and minimize toxicity. The authors also discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance.

  • #oncology

Like

Save

Share